We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Should CytomX Therapeutics (CTMX) Be On Your Radar Now?
Read MoreHide Full Article
It commonly happens in stock investing that investors miss the chance of buying winning stocks that they knew would stand out. Before they take the plunge, others get to know the hidden potential and enter into these stocks, pushing them out of reach.
So, instead of repenting, spotting the off-the-radar potential winners and immediately investing in them could be a smart decision.
One such company that looks well positioned for a solid gain, but has been overlooked by investors lately, is CytomX Therapeutics, Inc. (CTMX - Free Report) . This Medical - Biomedical and Genetics stock has actually seen estimates rise over the past month for the current fiscal year by about 30.4%. But that is not yet reflected in its price, as the stock lost 6.8% over the same time frame.
You should not be concerned about the price remaining muted going forward. This year’s expected earnings growth over the prior year is 21.6%, which should ultimately translate into price appreciation.
So if you are looking for a stock flying under-the-radar that is well-equipped to bounce down the road, make sure to consider CytomX Therapeutics. Solid estimate revisions and an impressive Zacks Rank suggest that better days may be ahead for CTMX and that now might be an interesting buying opportunity.
5 Trades Could Profit ""Big-League"" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Should CytomX Therapeutics (CTMX) Be On Your Radar Now?
It commonly happens in stock investing that investors miss the chance of buying winning stocks that they knew would stand out. Before they take the plunge, others get to know the hidden potential and enter into these stocks, pushing them out of reach.
So, instead of repenting, spotting the off-the-radar potential winners and immediately investing in them could be a smart decision.
One such company that looks well positioned for a solid gain, but has been overlooked by investors lately, is CytomX Therapeutics, Inc. (CTMX - Free Report) . This Medical - Biomedical and Genetics stock has actually seen estimates rise over the past month for the current fiscal year by about 30.4%. But that is not yet reflected in its price, as the stock lost 6.8% over the same time frame.
CytomX Therapeutics, Inc. Price and Consensus
CytomX Therapeutics, Inc. Price and Consensus | CytomX Therapeutics, Inc. Quote
You should not be concerned about the price remaining muted going forward. This year’s expected earnings growth over the prior year is 21.6%, which should ultimately translate into price appreciation.
And if this isn’t enough, CTMX currently carries a Zacks Rank #2 (Buy) which further underscores the potential for its outperformance (See the performance of Zacks' portfolios and strategies here: About Zacks Performance).You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
So if you are looking for a stock flying under-the-radar that is well-equipped to bounce down the road, make sure to consider CytomX Therapeutics. Solid estimate revisions and an impressive Zacks Rank suggest that better days may be ahead for CTMX and that now might be an interesting buying opportunity.
5 Trades Could Profit ""Big-League"" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>